Anti-østrogen

Numerous studies have shown that the growth of some tumors that occur in women may depend on the presence female sex hormones in a human body — estrogens. These tumors include breast cancer, cancer in the body of the uterus (endometrium), and ovarian cancer. By depriving tumor cells of “feeding” these hormones, it is possible to stop their growth and even achieve complete or partial disappearance of the tumor. To find out whether a particular tumor is dependent on estrogens, a special study is carried out to identify receptors for these hormones in tumor cells.

Attention! Aromatase inhibitors are effective for treating only tumors that produce estrogen receptors.

One important estrogen sources in a women body before menopause are the ovaries. After the onset of menopause, the estrogen production in the ovaries is sharply reduced and their level over whole body is sharply reduced. However, a small amount of them is continuously produced in other organs, most of them in adipose tissue. A minimal amount of estrogen may be sufficient to stimulate the growth of tumor cells. Estrogens are forming in it occurs due to specific work of a special enzyme (protein) — aromatase. Thus, if no formation of estrogens in the ovaries, suppression of aromatase activity leads to the termination of their formation in the body

Aromatase inhibitors drugs

Aromatase inhibitors are a class of drugs that suppresses this enzyme activity and therefore lower the level of estrogen in the body. With the use of aromatase inhibitors, tumor cells are deprived of their “feeding” with estrogens, their growth slows down or stops. This stops tumor progression, reduces the recurrence risk. It is important to note that aromatase inhibitors do not interfere with the formation of estrogen in the ovaries. For this reason, their use in patients who have not reached menopause (i.e., during ongoing menstruation) is not effective. Aromatase inhibitors are prescribed only for postmenopausal patients.

Most well known drugs are Letrozole, Anastrozole, Exemestane.

But in bodybuilding people often use some different drugs.

AntiEstrogen and bodybuilding

Aromatase inhibitors are considered to be Antiestrogens.

One of the most popular anti-estrogen drugs is Clomid (nolvadex). It is used by the athletes taking testosterone drugs after steroid course as estrogen blocker and to prevent the risks of gynecomastia.

One great fact about Clomid is that it can reduce muscles damage, after long intensive training. This feature is high appreciated by endurance athletes. It doesn’t affect gain of muscles. Clomid may also be reason for the mood changes and cause depression or symptoms reminding PMS but in very low percent of cases.

Clomid activating and blocking estro receptors depends on their location and type of tissue. There’s such a thing as co-factor that in combination with estrogen are in-flue estrogen receptors. Clomid may be a powerful inhibitor in hypothalamus and breast tissue that prevents gynecomastia.

As this drug alters hormonal balance in male body it is not advised to take it more then half of a year.

Better not to take it for women longer then two weeks.

Taking a course of testosterone anabolics try to find clomid nolvadex for sale. There many websites where you can buy clomid nolvadex estroblock and other aromatase inhibitors.

Østrogenreseptorantagonister og aromatasehemmere
Antiøstrogener kan ha en rekke effekter på hypofysehormonsekresjonen, avhengig av det omgivende hormonelle miljøet. Hos førmenopausale kvinner og voksne menn virker medisiner som klomifen, tamoksifen og raloksifen som østrogenantagonister og blokkerer de negative tilbakemeldingseffektene av østrogen på gonadotropinsekresjon, noe som resulterer i økt serum LH og FSH. I motsetning til det er motsatte effekter sett hos postmenopausale kvinner, hvor den svake østrogen-agonistiske aktiviteten til disse forbindelsene dominerer, noe som resulterer i delvis undertrykkelse av gonadotropinsekresjonen. Aromatasehemmere som letrozol og anastrazol øker også serumgonadotropiner hos menn.